COVID-19 vaccination in pregnancy, with or without influenza vaccine coadministration, was safe and well-tolerated by survey respondents and no new or worsening health problems were reported after coadministration of COVID-19 and influenza vaccines during pregnancy.
Abstract
Background
Despite consistent evidence of safety and efficacy of immunization against COVID-19, vaccine hesitancy remains prevalent among pregnant individuals. Reactogenicity (post-vaccination inflammatory symptoms) has been cited as a significant factor in decreasing vaccine acceptance. The seasonal overlap in the vaccination schedule for COVID-19 and influenza provides an opportunity to increase vaccine accessibility and uptake while decreasing healthcare burden through coadministration.
Methods
The Canadian COVID-19 Vaccine Registry for Pregnant Women and Pregnant People (COVERED) is a national prospective cohort study that enrolled pregnant participants in Canada, irrespective of vaccination status, from September 2023 to March 2024. Vaccine reactogenicity and significant health events (defined as a new or worsening health problem), within seven days of COVID-19 vaccination, were assessed using serial online surveys, and compared between those who received COVID-19 vaccine only and those who received concurrent COVID-19 and influenza vaccines (coadministration).
Results
Among 754 participants, 344 (45.6%) received COVID-19 vaccination during pregnancy, with 85 of 344 (24.7%) also receiving a same-day influenza vaccination. Within seven days of COVID-19 vaccination, the adverse events most reported were local injection site reaction (166/344 [48.3%]), fatigue (139/344 [40.4%]), and myalgia (135/344 [39.2%]). Increased rates of COVID-19 injection site reaction (57/85 [67.1%] vs. 109/259 [42.1%], p < .01) and chills (16/85 [18.8%] vs. 22/259 [8.5%], p = .03) were reported in those who received COVID-19 and influenza vaccines together when compared to those who received the COVID-19 vaccine alone. No new or worsening health problems were reported after coadministration of COVID-19 and influenza vaccines during pregnancy.
Conclusions
COVID-19 vaccination in pregnancy, with or without influenza vaccine coadministration, was safe and well-tolerated by survey respondents. Local injection site reaction and chills were more common after COVID-19 vaccination in those who also received a same-day influenza vaccination. There were no reports of significant health events after COVID-19 and influenza vaccine coadministration.
The findings suggest that tailored, evidence-based vaccine communication during antenatal care is particularly relevant for women with lower educational attainment, as well as a significant demographic divide.
Katarzyna Hinca, J. Jassem-Bobowicz, Iwona Jańczewska et al.· Frontiers in Public Health· 0 citations
Promising multicomponent influenza-COVID-19 vaccine candidates currently being evaluated in clinical trials may represent an important advancement in adult immunization strategy, and a meaningful opportunity to strengthen protection against two of the most consequential respiratory pathogens worldwide.
W. Schaffner, S. Gravenstein, S. Kissler et al.· Vaccine· 0 citations
INTRODUCTION
Individuals with Down syndrome are at increased risk for severe disease from acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, making them a priority group for COVID-19 vaccination. Data on vaccine uptake and factors associated with vaccination are needed to inform strategies to improve upta...
Nian Hui, T. Ding, Rees L. Lee et al.· Vaccine· 0 citations
Objective: The COVID-19 pandemic brought vaccination among healthcare workers (HCWs) back into focus. However, whether this experience was reflected in seasonal influenza vaccination remains unknown. This study aimed to evaluate HCWs’ COVID-19 vaccination status, motivations and concerns regarding vaccination, and self...
Emine Hafize Erdeniz, Bora Gürses, Şeyma Yeşilyurt et al.· Klimik Dergisi/Klimik Journa...· 0 citations
BACKGROUND
PICOBOO is a randomised, Bayesian adaptive trial evaluating immunogenicity and reactogenicity of licensed COVID-19 vaccines in immunocompetent individuals aged >12 years. We present reactogenicity data for nine vaccines administered as additional doses within adult strata based on age cohort and primary vacc...
McLeod C, M. Dymock, K. Flanagan et al.· Vaccine· 0 citations
This technical report accompanies the American Academy of Pediatrics policy statement recommendations for COVID-19 vaccination during the 2026-2027 respiratory virus season. The rationale is presented for recommending vaccination in all infants and children 6 through 23 months of age, children 6 months through 18 years...
Unknown authors· Pediatrics· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.